Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
2 hedge funds and large institutions have $1.85M invested in Eiger BioPharmaceuticals, Inc. in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 22 closing their positions.
42% less capital invested
Capital invested by funds: $3.19M → $1.85M (-$1.34M)
92% less funds holding
Funds holding: 24 → 2 (-22)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 22
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.25M |
| 2 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$450K |
| 3 |
AWP
Accretive Wealth Partners
Parsippany,
New Jersey
|
-$170K |
| 4 |
6CM
683 Capital Management
New York
|
-$148K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$141K |
EIGR Hedge Fund Activity: Q2 2024 in Review
2 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2024, worth a combined $1.85M — down 42% from $3.19M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of EIGR and 0 opened new positions — a net loss of 22 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Ameriprise, exiting entirely with an estimated $1.25M sold.
- 2 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2024, down from 24 in Q1 2024.
- Funds reported $1.85M of Eiger BioPharmaceuticals, Inc. stock for Q2 2024, down 42% quarter-over-quarter.
- 0 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2024 and 22 closed out, a net change of -22 holders.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2024 was Ameriprise, an estimated $1.25M sold.
Based on aggregated 13F filings for Q2 2024.